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Abstract
Background: HIV-1 Tat activates transcription of HIV-1 viral genes by inducing phosphorylation
of the C-terminal domain (CTD) of RNA polymerase II (RNAPII). Tat can also disturb cellular
metabolism by inhibiting proliferation of antigen-specific T lymphocytes and by inducing cellular
apoptosis. Tat-induced apoptosis of T-cells is attributed, in part, to the distortion of microtubules
polymerization. LIS1 is a microtubule-associated protein that facilitates microtubule
polymerization.
Results:  W e  i d e n t i f i e d  h e r e  L I S 1  a s  a Tat-interacting protein during extensive biochemical
fractionation of T-cell extracts. We found several proteins to co-purify with a Tat-associated
RNAPII CTD kinase activity including LIS1, CDK7, cyclin H, and MAT1. Tat interacted with LIS1
but not with CDK7, cyclin H or MAT1 in vitro. LIS1 also co-immunoprecipitated with Tat expressed
in HeLa cells. Further, LIS1 interacted with Tat in a yeast two-hybrid system.
Conclusion: Our results indicate that Tat interacts with LIS1 in vitro and in vivo and that this
interaction might contribute to the effect of Tat on microtubule formation.
Background
HIV-1 Tat protein is the viral transactivator encoded in the
HIV-1 genome of infected cells [1-3]. Tat stimulates for-
mation of full-length transcripts from the HIV-1 promoter
by promoting efficient transcript elongation (reviewed in
[4]). Tat interacts with the bulge of transactivation
response (TAR) RNA, a hairpin-loop structure at the 5'-
end of all nascent viral transcripts [5-7]. Tat induces elon-
gation of HIV-1 transcription by recruiting transcriptional
co-activators that include Postive Transcription Elonga-
tion Factor b (P-TEFb), an RNA polymerase II C-terminal
domain kinase [8-10] and histone acetyl transferases [11-
13]. Whereas P-TEFb induces HIV-1 transcription from
non-integrated HIV-1 template [8-10], histone acetyl
transferases allow induction of integrated HIV-1 provirus
[11-13]. Tat may also increase initiation of HIV-1 tran-
scription by enhancing phosphorylation of SP1, a tran-
scription factor involved in the basal HIV-1 transcription
[14]. In addition to its function in HIV-1 transcription, Tat
may contribute to HIV-1 pathogenesis by regulating signal
transduction in endothelial cells [15,16]; functioning as a
secreted growth factor for Kaposi sarcoma and endothelial
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cells [17]; and inducing apoptosis in T-cells by binding to
microtubules and delaying tubulin depolymerization
[18,19]. Tat induces apoptosis through BIM, a pro-apop-
totic protein of the Bcl-2 family that antagonizes Bcl-2
anti-apoptotic proteins [18]. The effect of Tat is similar to
the effect of Taxol, a drug that stabilizes microtubules and
induces apoptosis [18]. Mutations in the glutamine-rich
region of Tat protein (residues 60–72) were found to cor-
relate with rapid progression of HIV disease, and with
induction of apoptosis and binding to tubulin [20]. We
previously showed that microtubules polymerization is
facilitated by LIS1 protein [21], a causative factor for Lis-
sencephaly [22], a severe brain disorder resulted from
inefficient neuronal migration during early stages of brain
development [23]. LIS1, a 45 kDa protein, contains seven
repeating units called WD (Trp-Asp) repeats [24] that
form antiparallel sheets making up a toroidal propeller
structure [25]. WD repeats containing proteins are con-
fined to eukaryotes and participate in protein-proteins
interactions [24]. In addition to being a microtubule
binding protein, LIS1 is also a subunit of platelet-activat-
ing factor acetyl hydrolase (PAF-AH) [26]. LIS1 interacts
with dynein motor, NudC and Dynactin, a complex that
regulates microtubule dynamics [27,28]. LIS1 in addition
associates with Nudel [29], also a component of the
dynein motor complex, and this interaction affects
dephosphorylation of microtubules by protein phos-
phatase 2A (PP2A) [30]. Thus, LIS1 may function as a scaf-
fold that help to assemble dynein motor and serve to
regulate proper microtubule dynamics.
In the present paper, we fractionated extracts of Jurkat T-
cells using HIV-1 Tat as an affinity bait and RNAPII CTD
activity of the Tat-associated proteins as a selection crite-
ria. We identified by mass-spectrometry and immunob-
lotting components of the partially purified protein
fraction and found LIS1, CDK7, cyclin H, and MAT1. We
analyzed interaction of Tat with the identified individual
proteins and found that Tat interacts with LIS1. We con-
firmed this finding by co-immunoprecipitating Tat and
LIS1 from HeLa cells that were expressing Tat. And we also
confirmed binding of Tat to LIS1 in a yeast two-hybrid sys-
tem. Our results indicate that HIV-1 Tat interacts directly
with LIS1, and therefore this interaction might contribute
to the effect of Tat on microtubules formation in the cells.
Results
LIS1, CDK7, cyclin H, and MAT1 co-purify with Tat-
associated RNAPII CTD kinase activity
We reported previously that HIV-1 Tat associates with two
distinct protein kinase complexes purified from mitogen-
ically stimulated human primary T-lymphocytes; one
complex containing CDK2 and the other one CDK7 [31].
The CDK2-containing protein complex was previously
purified and characterized by us [32,33] and we showed
that CDK2 regulates HIV-1 transcription [34]. In the
present paper, we purify and characterize the CDK7-con-
taining protein elution peak. Whole-cell lysate from Jurkat
T cells was prepared and subjected to (NH4)2SO4 fraction-
ation as described previously [32]. In accord with our pre-
vious report [32], the 40% (NH4)2SO4 cut contained Tat-
associated CTD kinase activity (Fig. 1A). The 40%
(NH4)2SO4 cut was subsequently fractionated on DEAE-
Sepharose (Fig. 1B). As we previously reported, separation
of the ammonium sulphate cut on DEAE-Sepharose
resulted in the appearance of Tat-associated CTD hyper-
phosphorylating activity (Fig. 1B, fractions 34 to 36).
Hyperphosphorylated CTD (CTDo) migrated on SDS-
PAGE with a high degree of retardation, because of SDS
repelling effect. Immunoblotting of the DEAE-Sepharose
fractions 34 to 36 showed the presence of CDK7, CDK9
and a PSTAIRE-motif containing kinase, but not TFIIH
(See Additional File 1) in accordance with our previous
observations [32]. Further resolution of DEAE fractions
34–36 on SP-Sepharose column showed that part of the
Tat-associated CTD kinase activity was retained by the col-
umn and we previously identified this activity as contain-
ing CDK2 [32]. The other part of the Tat-associated CTD
kinase activity was not retained by the column and was
eluted as a flow-through fraction (Fig. 1C, flow through
fraction). This fraction was collected and further resolved
on Hi-Trap heparin column (Fig. 1D). Immunoblotting of
the Hi-Trap heparin fractions showed that Tat-associated
kinase activity co-eluted with CDK7 and also with cyclin
H, but not with CDK9 or a PSTAIRE-motif containing
kinase (Fig. 2A). Silver staining of the Hi-Trap heparin
fractions showed that fractions 22 and 24 contained three
protein bands of 35, 40, and 50 kDa which co-eluted with
the Tat-associated CTD kinase activity (Figure 2B; frac-
tions 22 and 24, protein bands marked by stars). The Hi-
Trap heparin fractions 22 to 24 were further analyzed on
Sephacryl S-300 gel filtration column to determine
whether CDK7, cyclin H and unknown protein bands
comigrate as a single macromolecular mass. Following gel
filtration on Sephacryl S-300, the Tat-associated CTD
kinase activity was found in the fractions corresponding
to the eluted proteins with a mass of 350 kDa (Fig. 3A,
fraction 16–18). Immunoblotting analysis showed that
CDK7, cyclin H (Fig. 3A) and MAT1 (not shown) co-
eluted with the Tat-associated CTD kinase activity. Frac-
tions 16–18 contain 32, 35, 40, 50 and 60 kDa protein
bands (Fig. 3B, protein bands marked by stars). To deter-
mine composition of unknown protein bands, fractions
22 to 24 were combined, concentrated on Centricon-10
spin column (Amicon), recovered in SDS-loading buffer
and resolved on 12% SDS-polyacrylamide gel. Following
staining with colloidal Coumassie blue, only two protein
bands of 35 and 50 kDa were visualized and subjected to
tryptic digestion and nanoelectrospray MS (described in
Experimental procedure section). The 35 kDa proteinRetrovirology 2005, 2:6 http://www.retrovirology.com/content/2/1/6
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Purification of Tat Associated CTD Kinase Figure 1
Purification of Tat Associated CTD Kinase. A, Ammonium sulfate fraction of T-cell extract. Whole cell extract of 
Jurkat T cells was fractionated by ammonium sulfate added sequentially to 10%, 20%, 40% and 80% saturation as described in 
Experimental procedures. Fractions were analyzed for Tat-associated CTD kinase activity as described in the Experimental proce-
dures section. A portion of each fraction was bound to GST-Tat 72 immobilized on glutathione-agarose beads and then incu-
bated with [γ-32P] ATP and recombinant GST-CTD. Phosphorylated GST-CTD was resolved on SDS/10%-(w/v)-PAGE. B, 
DEAE-Sepharose column-chromatographic elution profile. Jurkat T-cell extract 40%-(NH4)2SO4 cut was applied to a DEAE-
Sepharose column. Fractions were analyzed for Tat-associated CTD kinase activity as described above. C, SP-Sepharose col-
umn-chromatographic elution profile. DEAE-fractions 32 to 36 containing hyperphosphorylating CTD kinase activity were 
combined and applied to SP-Sepharose column. D, heparin-agarose column-chromatographic elution profile. SP-Sepharose 
flow-through fraction was collected and further fractionated on Hi Trap heparin column. Fractions 22 to 24 (labelled as puri-
fied complex) contained Tat-associated CTD hyperphosphorylating activity. Positions of CTDa and CTDo are shown. The fig-
ure is an autoradiogram.
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Analysis of protein composition of heparin-agarose purified fraction of Tat-associated CTD kinase Figure 2
Analysis of protein composition of heparin-agarose purified fraction of Tat-associated CTD kinase. A, Heparin-
agarose-purified fraction contains CDK7 but not CDK9. Fractions from the heparin-agarose column fractionation 
shown in Fig. 1 were analyzed by Western blotting with antibodies against CDK7, Cyclin H, PSTAIRE and CDK9. Fractions 22 
to 24 which contain Tat-associated CTD hyperphosphorylating activity also contain CDK7 and cyclin H, but not CDK9 or 
PSTAIRE-like kinase. B, Tat-associated CTD kinase co-purifies with 35, 40 and 50 kDa protein bands. Fractions from 
the heparin-agarose column fractionation were resolved on 12% SDS PAGE and stained with silver. Protein bands of 35, 40, 
and 50 kDa that co-purify with the CTD kinase activity are marked by stars.
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CDK7 and cyclin H co-migrate as a 350 kDa complex Figure 3
CDK7 and cyclin H co-migrate as a 350 kDa complex. Hi-Trap heparin fractions 22 to 24 were analyzed on Sephacryl 
S-300 gel filtration column. A, Tat-associated CTD kinase activity co-purify with CDK7 and cyclin H. Fractions from 
the Sephacryl S-300 column fractionation were analyzed for Tat-associated CTD kinase activity and also by Western blotting 
with antibodies against CDK7 and Cyclin H. B, Fractions from Sephacryl S-300 column fractionation were resolved by 12% SDS 
PAGE and stained with silver.
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contained peptides vpflPGDSDlDqltr and YPilENPEilr
(lower case letters indicate residues observed with less
than full confidence) with sequence identity to CDK7 and
cyclin H, respectively. The 50 kDa protein contained a
peptide VWDYETGDfER with sequence identity to LIS1.
HIV-1 Tat interacts with WD domains of LIS1 in vitro
Next we analysed which one of the identified proteins in
the elution complex might interact with Tat. We expected
that CDK7 might bind to Tat as their interaction was pre-
viously reported [35]. We incubated fractions 18 to 24
with GST-fused Tat 1–72, then precipitated GST-Tat with
glutathione-agarose beads and analysed associated pro-
teins on SDS-PAGE followed by a silver staining. We
found that a 50 kDa protein associated with GST-Tat in
fractions 20 and 22 (see Additional file 2, lanes 3 and 4).
We then asked whether LIS1, a candidate for a 50 kDa Tat-
interacting protein, binds to Tat. We translated LIS1 and
also translated as controls CDK7, cyclin H and MAT1, in
reticulocyte lysate (Fig. 4A) and performed GST pull down
assays using GST-fused Tat 1–72 (Fig. 4B). LIS1 bound to
Tat (Fig. 4B, lane 4). In contrast, almost no binding was
detected for CDK7, cyclin H or MAT1 (Fig. 4B, lanes 1 to
3). These results contrasted with the previous report in
which recombinant Tat interacted with CDK7 immunop-
urified from reticulocyte lysate [35]. The main difference
of our study was that we used programmed lysates rather
than purified proteins. Immunoaffinity analysis showed
that reticulocyte lysate contains substantial amount of
endogenous LIS1 which is comparable to the amount of
LIS1 in the LIS1-programmed lysate (see Additional file 3,
compare lanes 1–3 to lane 4). Thus the excess of LIS1
might compete for the binding to Tat and prevent CDK7
interaction with Tat. To analyze whether WD domains of
LIS1 might associate with Tat, we expressed each of WD
domain, except domain 2 as well as the N-terminal part of
LIS1, which contains a coiled-coiled motif and which is
devoid of WD domains. The WD domain 1, 4, 5 or 7
bound to Tat (Fig. 4B, lanes 6 to 11). Also the N-terminal
portion of LIS1 bound weakly to Tat (Fig. 4B, lane 5). To
analyze specificity of the binding and to determine a
domain of Tat that binds LIS1, several Tat mutants were
utilized including Tat 1–72, Tat 1–48, and Tat 37–72 and
also GST as a control (Fig. 5). Full length LIS1 bound with
equal efficiency to a full length Tat, Tat 1–48 or Tat 37–72
but not to GST alone (Fig. 5, lanes 2 to 5). In contrast, iso-
lated WD5 domain of LIS1 bound most efficiently to the
full length Tat 1–72 and less efficiently to Tat 1–48 or to
Tat 37–72 (Fig. 5, lanes 6 to 9). The isolated N-terminal
domain of LIS1 bound strongly to GST (Fig. 5, lane13),
and thus its weak binding to GST-Tat (Fig. 5, lane 12) is
likely to be mediated by the binding to the GST moiety.
Tat co-immunoprecipitates with LIS1 from HeLa cellular 
extracts
To analyze interaction of Tat with LIS1 in cultured cells,
co-immunoprecipitation analysis was performed. Tat was
expressed in HeLa cells infected with adenovirus vector
expressing Flag-tagged Tat [36]. Tat expression in the
extract was verified by immunoblotting analysis with anti-
Flag antibodies (Fig. 6A, compare lane 2 to lane 1) and
also with anti-Tat antibodies (not shown). LIS1 was
expressed equally in control cells without Tat and in the
cells expressing Flag-Tat (Fig. 6B, lanes 1 and 2). Tat co-
precipitated with LIS1 when LIS1 was immunoprecipi-
tated with LIS1-specific monoclonal antibodies, resolved
by 12% Tris-Tricine PAGE and immunoblotted with anti-
Flag antibodies (Fig. 6A, lane 3). No Tat was detected in
the control immunoprecipitation (Fig. 6A, lane 4). Simi-
lar, LIS1 co-precipitated with Tat when Flag-Tat was
immunoprecipitated with anti-Tat polyclonal antibodies,
resolved by 10% Tris-Tricine PAGE and immunoblotted
with anti-LIS1 antibodies (Fig. 6B, lane 3). No LIS1 was
detected in the control immunoprecipitation (Fig. 6B,
lane 4). These results indicate that Tat associates with LIS1
in cultured cells.
Tat binds to LIS1 in yeast two-hybrid system
To analyze whether Tat interacts with LIS1 directly and
not through another protein, we utilized LexA-based yeast
two hybrid system (Clontech, see details in Experimental
procedures). EGY48 yeast cells pretransformed with
pSH18–34 reporter plasmid (-Ura selection) were further
transformed with different combinations of pJG-LIS1 or
pJG4–5 empty vector (-Trp selection) and pLexA Tat or
pLexA empty vector (-His selection). Colonies grown on-
His/-Trp/-Ura media with glucose were plated on Galac-
tose/Raffinose His /-Trp/-Ura plates, to induce LIS1 and
Tat production. The plates also contained 5-Bromo-4-
Chloro-3-Indolyl-β-D-galactopyranoside (X-Gal)
substrate for β-galactosidase. Tat interacted with LIS1 as it
was detected by development of blue color upon conver-
sion of X-gal (Fig. 7D). In contrast Tat did not interact
with the acid activation domain alone (Fig. 7C). Also no
interaction was detected for LexA DNA binding domain
and acid activation domain (Fig. 7A) or LexA DNA bind-
ing domain and LIS1 (Fig. 7B).
Taken together, these results indicate that LIS1 directly
and specifically binds to Tat in vivo.
Discussion
In this study, we show that HIV-1 Tat protein associates
with LIS1 protein. LIS1, a microtubule binding protein
[21] contains WD repeats [24] that are likely to participate
in protein-protein interactions [24]. LIS1 regulates micro-
tubule dynamics by interacting with dynein motor, NudC
and Dynactin [27,28] and also with Nudel [29]. A yeastRetrovirology 2005, 2:6 http://www.retrovirology.com/content/2/1/6
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LIS1 binds to HIV-1 Tat in vitro Figure 4
LIS1 binds to HIV-1 Tat in vitro. Individual protein components of Tat-associated complex were translated in reticulocyte 
lysate containing [35S]methionine as described in the Experimental procedures section. A, Input lysates, resolved on 12% SDS-
PAGE. Lane 1- CDK7; Lane 2-Cyclin H; Lane 3-MAT1; Lane 4-LIS1; Lane 5-the N-terminal domain of LIS1 (LIS NT); Lane 6- 
WD7; Lane 7-WD6; Lane 8 – WD5; Lane 9 – WD4; Lane 10- WD3; and Lane 11- WD1. B, programmed reticulocyte lysates 
from panel A precipitated with GST-Tat 72 immobilized on glutathione-agarose beads, and resolved on 12% SDS-PAGE.
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homologue of LIS1, NudF associates with NudC to regu-
late dynein and microtubule dynamics [37,38]. Thus,
interaction of Tat with LIS1, a scaffold that assembles
dynein motor, may affect microtubule dynamics.
We purified several candidate proteins that might interact
with Tat, and found CDK7, cyclin H, MAT1 and LIS1. We
expected that CDK7 might bind to Tat as previously it was
shown to interact directly with Tat [35]. In contrast, anal-
ysis of the binding of individually translated proteins
showed that LIS1 and not CDK7 bound to Tat. We
hypothesized that WD domain(s) of LIS1 might bind Tat,
as these domains form a planar surface. Correspondingly,
domains WD1, WD4, WD5 and WD7 were found to bind
Tat but not the N-terminal part of LIS1 that contains coil-
coil region, and which is devoid of WD domains. We ana-
lyzed whether a particular domain of Tat binds LIS1 or
WD5 domain of LIS1. Full length Tat 1–72 was most effi-
cient in binding of either LIS1 or WD5 domain of LIS1. It
would be interesting to determine whether CDK7 also
binds to LIS1, and whether LIS1 promotes activation of
the kinase activity of CDK7 by Tat. Although LIS1 is a
cytoplasmic protein, it may be required for initial assem-
bly of a protein complex containing CDK7. Our results
contrasted with the previous report in which Tat binds to
purified CDK7 [35]. We hypothesize that under our
experimental conditions, excess of endogenous LIS1
present in the reticulocyte lysate might compete with
interaction of Tat with CDK7. Interestingly, Gaynor an
colleagues only detect specific interaction of Tat with
TFIIH but not with of CDK7 or CAK alone [39]. Therefore,
it is possible that in a complex protein mixture Tat inter-
acts with CDK7 indirectly through another protein such as
LIS1.
To explore interaction of Tat and LIS1 in cultured cells,
Flag-tagged Tat was expressed in HeLa cells and then
immunoprecipitated with anti-Flag-antibodies. LIS1 was
found to co-immunoprecipitate with Tat. Correspond-
ingly, when LIS1 was immunoprecipitated with anti-LIS1
monoclonal antibodies, Flag-Tat was found in the immu-
noprecipitates. These results suggest that Tat associates
with LIS1 in cultured cells. To confirm that LIS1 and Tat
interact in vivo, we used yeast two-hybrid system, in which
Tat was expressed as a bait and LIS1 as a prey. Again, we
found that LIS1 and Tat interacted in this system. Taken
together, our in vitro and in vivo results demonstrate that
WD5 domain of LIS1 interact with HIV-Tat Figure 5
WD5 domain of LIS1 interact with HIV-Tat. LIS1, 
WD5 domain of LIS1 (WD5) and N-terminal portion of LIS1 
(LIS1 NT) were translated in reticulocyte lysate containing 
[35S] methionine as described in the Experimental proce-
dures section. Lysates were precipitated with GST-fused Tat 
1–72, Tat 1–48, Tat 37–72 or GST alone, immobilized on glu-
tathione-agarose beads, and resolved on 12% SDS-PAGE. 
Lanes 1, 6 and 11 – Input; Lanes 2, 7 and 12 – precipitation of 
LIS1, WD5 or LIS1 NT with Tat 1–72; Lanes 3 and 8 – pre-
cipitation of LIS1 and WD5 with Tat 1–48; Lanes 4 and 9 – 
precipitation of LIS1 and WD5 with Tat 37–72; Lanes 5, 10 
and 13 – precipitation of LIS1, WD5 or LIS1 NT with GST 
alone. The figure is an autoradiogram.
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HIV-1 Tat binds to LIS1 and that this binding is likely to
occur through one of the WD domains of LIS1.
Tat contains several functionally important regions,
including the N-terminal region I (residues 1–21);
cystein-rich region II (residues 22–37); core region III
(residues 38–48); basic region IV (residues 49–59);
glutamine-rich region V (residues 60–72); and C-terminal
region VI [20,40]. Zhou and his colleagues showed that
Tat interacts with microtubules through parts of region II
(residues 35–37) and region III (residue 38) [18]. More
recently, Loret and his colleagues showed that the
glutamine-rich region of Tat may also interact with micro-
tubules and promote apoptosis in T cells [20]. In a follow-
ing study which will appear in the same issue of
Retrovirology, Loret and his colleagues show that Tat res-
idues 38–72 are sufficient to enhance microtubule polym-
erization and that the extent of the enhancement
correlates with the severity of Tat-induced apoptosis[41].
Taken together these studies indicate that residues 35–38
of regions II and III and glutamine-rich region of Tat may
interact with microtubules. These results correlate well
with our finding that full length Tat binds LIS1 better than
the isolate domains of Tat. Whether LIS1, a cellular struc-
tural protein and also an enzymatic subunit of PAF-AH,
plays a role in Tat-induced apoptosis remained to be
LIS1 interacts with Tat in yeast two-hybrid assay Figure 7
LIS1 interacts with Tat in yeast two-hybrid assay. EGY48 yeast cells were transformed, as described in Experimental pro-
cedures, with pSH18–34 reporter and combinations of pLexA and pJG4–5 empty vectors (panel A); pLexA and pJG LIS1 (panel 
B); pLexA Tat and pJG 4–5 (panel C); pLexA Tat 86 and pJG LIS1 (panel D). Six independent colonies from each transformation 
were cultured on plates containing Galactose/Raffinose to induce Tat and LIS1 synthesis and X-Gal substrate to detect β-galac-
tosidase.
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determined. As Tat-associated proteins include CDK7,
Cyclin H, MAT1 and LIS1, it is possible that interaction of
Tat with LIS1 might promote binding of CDK7 and ulti-
mately affect viral gene expression through a direct
activation of CDK7 or indirectly through activation of a
down stream kinase, CDK2, by CDK7. As Tat is shuttling
between nucleus and cytoplasm, its interaction with LIS1
and CDK7-containing protein complex might allow a
temporary activation/modulation of the CDK7 activity. It
is remained to be determined whether such interaction
has an effect on Tat-induced transcription of HIV-1 genes.
LIS1 may also function as an adaptor that brings HIV-1
Tat to microtubules that may release microtubules-associ-
ated BIM-1 protein and induce apoptosis [18]. A more
detailed future study will address the questions of the reg-
ulation of HIV-1 transcription and Tat-mediated apopto-
sis by LIS1.
Methods
Materials
Jurkat T-cells were purchased from National Cell Culture
Center (CELLEX BIOSCIENCES, MN). DEAE-Sepharose
(FF), SP-Sepharose (FF), Hi Trap heparin columns, [γ-32P]
ATP (6000 Ci/mmol) and (35S)-labeled Methionine were
purchased from Amersham Pharmacia Biotech
(Piscataway, NJ). Econo-Pac CHT-II Cartridge (ceramic
hydroxyapatite) was from Bio-Rad (Hercules, CA). Glu-
tathion-agarose was from Sigma (Atlanta, GA). GST-CTD
was expressed in Escherichia coli and purified as we
described [32]. The Tat expression plasmids GST-Tat (1–
72), GST-Tat (1–48), GST-Tat (37–72) were obtained
from AIDS Research and Reference Reagents Program
(NIH), expressed in Escherichia coli and purified on Glu-
tathione-agarose beads as described [31]. CDK7, cyclin H
and MAT1 expression vectors were kindly provided by Dr.
Marcel Doreé (CNRS, Montpellier, France). Coupled tran-
scription/translation system based on rabbit reticulocyte
lysate was purchased from Ambion (Austin, TX). Protein
(G) and protein (A) agarose were purchased from Sigma
(Atlanta, GA).
Antibodies
Anti-Tat rabbit polyclonal (HIV-1 BH10 Tat antiserum)
and monoclonal (NT3 2D1.1) antibodies were received
from AIDS Research and Reference Reagents Program
(NIH). Anti-Flag antibodies were purchased from Sigma
(Atlanta, GA). Polyclonal antibodies to CDK7, and
PSTAIRE were purchased from Santa Cruz Biochemical
(Santa Cruz, CA). Polyclonal antibody to CDK9
(PITALRE) were purchased from Biodesign Company
(Saco, ME). Monoclonal antibodies for LIS1 were as
described [21].
Tat-associated CTD kinase assay
Tat-associated kinase activity was assayed as described
previously [32]. Briefly, portions of eluted fractions
(about 1/1000 of the total amount) from each chroma-
tography column were incubated with 10 µg of GST-Tat
(1–72) immobilized on glutathione-agarose beads for 1
hour at 4°C. The beads were washed with the buffer B
containing 20 mM HEPES (pH 7.9), 250 mM NaCl, 1%
NP-40, 5 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF and 10
µg/ml aprotinin, followed by washing with the kinase
buffer (50 mM HEPES (pH 7.9), 10 mM MgCl2, 6 mM
EGTA and 2.5 mM dithiothreitol). Tat-associated CTD
kinase activity was assayed by incubating the kinase-
bound beads with 100 ng GST-CTD in kinase buffer con-
taining 50 µM ATP and 10 µCi of ( 32p)ATP for 10 min
at room temperature. Phosphorylated GST-CTD was
resolved on 10% SDS-PAGE and subjected to
autoradiography and quantification with PhosphorIm-
ager Storm 860 (Molecular Dynamics).
Purification of Tat-associated CTD kinase
Purification of Tat-associated CTD kinase from Jurkat T-
cells was carried as previously described [32]. Briefly, 100
liters of Jurkat T cell culture at concentration of 5 × 105
cells/ml were centrifuged, washed and Dounce-homoge-
nized in Buffer A (50 mM HEPES [pH 7.9], 5 mM EDTA,
0.5 mM DTT, 0.5 mM PMSF, 10 µg/ml aprotinin and 10%
glycerol) supplemented with 0.1% NP-40. The whole cell
extract was prepared and fractionated by ammonium sul-
fate precipitation. Ammonium sulfate was added to 10%
saturation to extract nuclei. After centrifugation, the
supernatant, containing approximately 10 g of protein,
was further fractionated with ammonium sulfate added to
20%, 40% and 80% saturation. The 40% ammonium sul-
fate fraction (about 3.5 g of protein) was found to contain
the major part of Tat-associated CTD kinase activity. This
fraction was diluted with Buffer A until the conductivity
was equivalent to 50 mM KCl and then loaded on a DEAE-
Sepharose column (about 500 mg of protein per 50 ml
column). The column was eluted with a linear gradient of
KCl (0.1 to 1 M) in Buffer A. Fractions were assayed for
Tat-associated CTD kinase activity as described above. A
peak of Tat-associated CTD kinase activity was collected,
diluted with Buffer A until conductivity was equivalent to
50 mM KCl and loaded on a 10 ml SP-Sepharose column
which was eluted with linear gradient of KCl (0.1 to 1 M)
in Buffer A. A flow-through fraction containing Tat-associ-
ated CTD kinase activity was further fractionated on Hi
Trap heparin columns (1 ml, three in series). Fractions
were collected and analyzed for the Tat-associated CTD-
kinase activity as described above, as well as by immuno-
blotting. Fractions containing Tat-associated CTD kinase
activity TTK were resolved on 12% SDS-PAGE (20 × 20
cm) stained with colloidal Coumassie Blue and subjected
to protein microsequencing.

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NanoLC ion trap mass spectrometry and peptide 
sequencing
The procedure for peptide sequencing was performed as
described previously. Protein bands visible after colloidal
Coomassie blue staining and corresponding to the peak of
CTD hyperphosphorylating activity after the heparin-aga-
rose column were subjected to in-gel reduction, carboxya-
midomethylation and tryptic digestion (Promega,
Madison, WI). Multiple peptide sequences were deter-
mined in a single run by microcapillary reverse-phase
chromatography directly coupled to a Finnigan LCQ
quadrupole ion trap mass spectrometer equipped with a
custom nanoelectrospray source. The column was packed
in-house with 5 cm of C18 support into a New Objective
one-piece 75 um I.D. column terminating in a 15 µm tip.
Flow rate was 190 nanoliters/min. The ion trap was pro-
grammed to acquire successive sets of three scan modes
consisting of full scan MS over alternating ranges of 395–
800 m/z or 800–1300 m/z, followed by two data depend-
ent scans on the most abundant ion in those full scans.
These data dependent scans allowed the automatic acqui-
sition of a high resolution (zoom) scan to determine
charge state and exact mass, and MS/MS spectra for pep-
tide sequence information. MS/MS spectra were acquired
with a relative collision energy of 30%, an isolation width
of 2.5 Dalton and recurring ions dynamically excluded.
Interpretation of the resulting MS/MS spectra of the pep-
tides was facilitated by programs developed in the Har-
vard Microchemistry Facility and by database correlation
with the algorithm SyQuest [42].
In vitro proteins synthesis
Proteins were transcribed/translated as described previ-
ously [32]. Briefly, the CDK7, cyclin H and MAT1, LIS1
and different domains of LIS1 were transcribed/translated
in a coupled rabbit reticulocyte system according to man-
ufacturer recommendations (Ambion, Austin, TX). Pro-
teins were resolved on 12% SDS-PAGE. The gel was
treated with Amplify solution (Amersham Pharmacia Bio-
tech, Piscataway, NJ), dried and exposed to X-ray film
with intensifying screen at -70°C.
Co-immunoprecipitation and Western blot
HeLa cells were infected with adenovirus vector expressing
Flag-tagged Tat protein as we previously described [36].
HeLa whole cell extracts were prepared as described previ-
ously [43]. Cell extracts were also prepared from non-
infected HeLa cells and used as a control. About 100 µg of
whole cell extract was supplemented with 5 µg of anti-Flag
or anti LIS1 antibodies. Then protein G-agarose beads pre-
blocked with 5% BSA and suspended in TNN buffer (50
mM Tris-HCl (pH 7.5), 0.5% NP-40, 150 mM NaCl)
buffer were added and the reaction was incubated in TNN
buffer at 4°C for 2 h with rocking. The beads were precip-
itated and washed once with TNN buffer and once with
the kinase buffer (50 mM HEPES-KOH (pH-7.9), 10 mM
MgCl2, 6 mM EGTA, 2.5 mM DTT). The pellet was then
resuspended in a 30 µl of 1X SDS loading buffer (4% SDS,
10% glycerol, 5% 2-mecarpthaethanol, 0.002%
bromophenol blue) and heated at 90°C for 3 minutes.
The proteins were resolved on SDS Tris-Tricine PAGE,
10%, to detect LIS1, or 12%, to detect Tat, and immunob-
lotted with anti-LIS1 or anti-Flag antibodies.
Yeast two-hybrid system
The parent yeast cells EGY48 (LexA 2H) genotype (MATα,
ura3, his3, tryp1, LexAop (x6) -LEU2), auxotrophic for tryp-
tophan (Trp), uracil (Ura), histidine (His), with LEU2 as
a reporter gene. Yeast were transformed by electropora-
tion as follow. One colony of the yeast cells was resus-
pended into 10 ml of appropriate selective media and
grown at 30°C overnight. Cells were collected at 3000
rpm for 10 min, washed twice with HEPES/Sorbitol (20
mM HEPES pH 7.9, 1 M Sorbitol), resuspended in 200 µl
of HEPES/Sorbitol and supplemented with 1 µg of a plas-
mid DNA. The mixture was pulsed with 2500 V in 0.4 cm
cuvette, then 1 ml of appropriate selective media was
added and cells were shaken at 30°C for 2 hours. The cells
were collected by centrifugation, resuspended into 250 µl
of HEPES/Sorbitol and plated on appropriate selective
plates. EGY48 cells were transformed with pSH18–34 vec-
tor containing Lac Z reporter under the control of Lex-
Aop(x8) and also URA3 and ampr genes as selection markers.
The transformed yeast cells (EGY48-lacZ) were selected on
Uracyl deficient media. HIV-1 Tat first exon was sub-
cloned into pLexA in frame with the LexA(1–202), the DNA
binding domain to create the bait vector (pLexA-Tat). LIS1
was subcloned into pJG 4–5 (ampr) in frame with the acid
activation domain to create pJG-LIS1 carrying
hemagglutinin (HA) tag (Trp selectable marker). The
EGY48-lacZ yeast cells were transformed with pLexA-Tat
vector, and selected for growth on uracyl and histidine
deficient media. The Tat expressing yeast cell growing on
Uracyl, Histidine deficient plates were then transformed
with pJG-LIS1. To detect interaction between Tat and LIS1
interaction, yeast cells were plated on galactose/raffinose-
containing plates to allow expression of Tat and LIS1, and
production of β-galactosidase was visualized with 5-
bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal)
substrate.
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